全球檢查室開發測試市場規模、佔有率、趨勢和成長分析報告（2026-2034）

實驗室自建檢測 (LDT) 市場預計將從 2025 年的 106.8 億美元成長到 2034 年的 194 億美元，2026 年至 2034 年的複合年成長率為 6.86%。

隨著醫療機構對針對特定患者需求的客製化診斷解決方案的需求不斷成長，全球實驗室自建檢測（LDT）市場持續擴張。 LDT在檢測罕見疾病、遺傳性疾病和複雜感染疾病發揮著至關重要的作用。其柔軟性和可自訂性使其在先進的臨床檢查室中極具價值，尤其是在腫瘤學和個人化醫療領域。

對早期精準疾病診斷日益成長的需求是推動成長要素。癌症、感染疾病和慢性病病例的不斷增加促使檢查室開發自主研發的檢測方案。分子診斷、次世代定序和生物標記鑑定等技術的進步也為市場擴張提供了支持。此外，精準醫療意識的不斷提高也促進了實驗室自建檢測（LDT）在臨床決策中的應用。

未來，市場可望在更完善的法規結構和品質標準下發展，以確保可靠性和安全性。人工智慧在診斷領域的應用以及基因組檢測的擴展將進一步提高檢測的準確性和效率。隨著醫療系統優先考慮個人化治療方案，檢查室開發的檢測方法很可能仍將是現代診斷服務的重要組成部分。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球檢查室開發測試市場：依測試類型分類

• 市場分析、洞察與預測
• 臨床生物化學
• 免疫學
• 血液學
• 微生物學
• 分子診斷
• 流式細胞技術
• 組織學/細胞學
• 其他類型的測試

第5章：全球檢查室開發與測試市場：按應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 遺傳學
• 感染疾病
• 自體免疫疾病
• 神經病學
• 精神和行為障礙
• 營養和代謝紊亂
• 其他用途

第6章：全球檢查室開發與測試市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院檢查室
• 診斷中心
• 臨床研究機構
• 學術研究機構
• 其他最終用戶

第7章 全球檢查室開發測試市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • 23andMe Inc
  • Abbott
  • Bio-Rad Laboratories Inc
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • NeoGenomics Laboratories
  • OPKO Health Inc
  • QIAGEN
  • Quest Diagnostics Incorporated

The Laboratory Developed Tests Market size is expected to reach USD 19.40 Billion in 2034 from USD 10.68 Billion (2025) growing at a CAGR of 6.86% during 2026-2034.

The Global Laboratory Developed Tests (LDTs) Market is expanding as healthcare providers seek specialized diagnostic solutions tailored to specific patient needs. LDTs play a critical role in detecting rare diseases, genetic conditions, and complex infections. Their flexibility and customization make them highly valuable in advanced clinical laboratories, particularly in oncology and personalized medicine applications.

Rising demand for early and accurate disease diagnosis is a major growth driver. Increasing cases of cancer, infectious diseases, and chronic conditions have encouraged laboratories to develop in-house testing solutions. Technological advancements in molecular diagnostics, next-generation sequencing, and biomarker identification are also supporting market expansion. Additionally, growing awareness about precision medicine is boosting the adoption of LDTs in clinical decision-making.

In the future, the market is expected to evolve with stronger regulatory frameworks and quality standards to ensure reliability and safety. Integration of artificial intelligence in diagnostics and expansion of genomic testing will further enhance test accuracy and efficiency. As healthcare systems prioritize personalized treatment approaches, laboratory developed tests are likely to remain a vital component of modern diagnostic services.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Clinical biochemistry
• Immunology
• Haematology
• Microbiology
• Molecular diagnostics
• Flow cytometry
• Histology/Cytology
• Other test types

By Application

• Oncology
• Genetics
• Infectious diseases
• Autoimmune disorders
• Neurology
• Mental/Behavioral disorder
• Nutritional & metabolic diseases
• Other applications

By End-use

• Hospital laboratories
• Diagnostic centers
• Clinical research organizations
• Academic and research institutes
• Other end-users

COMPANIES PROFILED

• 23andMe Inc, Abbott, BioRad Laboratories Inc, Eurofins Scientific, F HoffmannLa Roche Ltd, Illumina Inc, NeoGenomics Laboratories, OPKO Health Inc, QIAGEN, Quest Diagnostics Incorporated
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Clinical biochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Haematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Microbiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Molecular diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Flow cytometry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Histology/Cytology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Other test types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Genetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Mental/Behavioral disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Nutritional & metabolic diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospital laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical research organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Academic and research institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other end-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LABORATORY DEVELOPED TESTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 23andMe Inc
  • 9.2.2 Abbott
  • 9.2.3 Bio-Rad Laboratories Inc
  • 9.2.4 Eurofins Scientific
  • 9.2.5 F. Hoffmann-La Roche Ltd
  • 9.2.6 Illumina Inc
  • 9.2.7 NeoGenomics Laboratories
  • 9.2.8 OPKO Health Inc
  • 9.2.9 QIAGEN
  • 9.2.10 Quest Diagnostics Incorporated